Literature DB >> 1467195

The impact of nausea and vomiting upon quality of life measures.

J M Bliss1, B Robertson, P J Selby.   

Abstract

The measurement of quality of life in cancer patients has achieved prominence in recent years. This results from recognition of the limitations of available therapies and a clearer view of the goals of treatment in patients whose diseases may not be curable. Many different approaches to the measurement of quality of life have been proposed and these will be reviewed. In a recent survey of available methods, the Medical Research Council's Working Party on Quality of Life Measurement systematically analysed available instruments for measuring quality of life specifically in cancer patients and commented on a number of instruments of general purpose that may be used in oncology. It was concluded that no instrument is entirely satisfactory for all purposes and that available instruments have to be selected carefully for a particular study or a particular aspect of clinical practice. However, among the existing instruments, the Rotterdam Symptom Checklist for a general assessment of many facets of quality of life and the Hospital Anxiety and Depression Scale, for detecting psychosocial morbidity quickly and easily, were useful. In our own studies we have used a multiple linear analogue scale system to measure aspects of quality of life in breast cancer patients and have recently addressed the determinants of overall quality of life. Our studies identify the importance of evaluating the psychometric properties of measurement instruments in quality of life. Reliability and validity and the ability to discriminate changes with time and between clinically distinct groups have to be carefully assessed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1467195      PMCID: PMC2149645     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  20 in total

1.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

2.  Quality of life measurements in patients with malignant disease: a review.

Authors:  A Clark; L J Fallowfield
Journal:  J R Soc Med       Date:  1986-03       Impact factor: 5.344

3.  Comprehensive follow-up of carcinoma patients.

Authors:  F C Izsak; J H Medalie
Journal:  J Chronic Dis       Date:  1971-07

4.  Assessment of the quality of life of patients with advanced cancer.

Authors:  I R Gough; C M Furnival; L Schilder; W Grove
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

5.  A scale of valuations of states of illness: is there a social consensus?

Authors:  R Rosser; P Kind
Journal:  Int J Epidemiol       Date:  1978-12       Impact factor: 7.196

6.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

7.  Evaluation of quality of life in patients receiving treatment for advanced breast cancer.

Authors:  T J Priestman; M Baum
Journal:  Lancet       Date:  1976-04-24       Impact factor: 79.321

8.  A measure of primary sociobiological functions.

Authors:  S Katz; C A Akpom
Journal:  Int J Health Serv       Date:  1976       Impact factor: 1.663

9.  Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.

Authors:  J C de Haes; F C van Knippenberg; J P Neijt
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

10.  The development of a method for assessing the quality of life of cancer patients.

Authors:  P J Selby; J A Chapman; J Etazadi-Amoli; D Dalley; N F Boyd
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

View more
  7 in total

1.  Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.

Authors:  Cesare Gridelli; Amin M Haiderali; Mark W Russo; Linda M Blackburn; Konstantinos Lykopoulos
Journal:  Support Care Cancer       Date:  2009-10-31       Impact factor: 3.603

Review 2.  Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  G L Plosker; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

3.  Health-related quality of life (HRQoL) in patients with cancer and other concurrent illnesses.

Authors:  Barbara A Elliott; Colleen M Renier; Irina V Haller; Thomas E Elliott
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

Review 4.  The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

Authors:  Michael S Broder; Claudio Faria; Annette Powers; Jehangeer Sunderji; Dasha Cherepanov
Journal:  Am Health Drug Benefits       Date:  2014-05

5.  Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.

Authors:  Thomas Bechtel; Ali McBride; Brooke Crawford; Susan Bullington; Craig C Hofmeister; Don M Benson; Samantha Jaglowski; Sam Penza; Leslie A Andritsos; Steven M Devine
Journal:  Support Care Cancer       Date:  2014-05-17       Impact factor: 3.603

6.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

Authors:  M de Boer-Dennert; R de Wit; P I Schmitz; J Djontono; V v Beurden; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.

Authors:  Enzo Ballatori; Fausto Roila
Journal:  Health Qual Life Outcomes       Date:  2003-09-17       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.